#USA #New York #Gross Law Firm #Ultragenyx #RARE

Class Action Lawsuit Notice for Ultragenyx Pharmaceutical Investors

In a recent announcement, the Gross Law Firm has reminded shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a pending class action lawsuit. Shareholders who purchased stock within the specified class period are encouraged to reach out to the law firm for potential lead plaintiff consideration. It's important to note that one does not have to be appointed as a lead plaintiff to be eligible for any recovery stemming from the lawsuit.

The class period established for this action ranges from August 3, 2023, to December 26, 2025, giving shareholders a specific window during which they can seek restitution for their losses. According to the allegations within the complaint, Ultragenyx's management made overly optimistic statements about their study protocols and the potential of their drug setrusumab. However, these assertions were allegedly built upon materially false and misleading information.

Significantly, while setrusumab was confirmed to increase bone mineral density, this benefit did not translate into a reduced rate of fractures among patients, contrary to management's claims. As a result of this misrepresentation, the outcomes from the Phase III Orbit and Cosmic studies were significantly less favorable than represented. On December 29, 2025, the company disclosed that these studies failed to meet their primary endpoint, which was to show a reduction in clinical fracture rates when compared to placebo treatments. This news led to a drastic decline in Ultragenyx’s stock price, plunging approximately 42.32% in one day — from $34.19 to $19.72 per share.

Given this situation, affected shareholders are strongly encouraged to take steps without delay. The deadline to formally register for this class action and potentially become a lead plaintiff is April 6, 2026. Interested shareholders can register online and will subsequently be integrated into a monitoring system that provides ongoing updates and status reports throughout the litigation process.

To participate, shareholders need to submit their information via the Gross Law Firm's established link. There’s no cost for joining the action, ensuring that shareholders can pursue their rights without facing financial burden.

The Gross Law Firm, a recognized name in the realm of class action litigation, aims to uphold the rights of all investors who have suffered due to dishonest practices, fraud, or misleading business operations. Their commitment ensures that corporations uphold responsible practices, and the firm seeks reparations for investors whose losses stem from misleading claims.

Summary of Key Information:

• - Class Period: August 3, 2023, to December 26, 2025
• - Lead Plaintiff Deadline: April 6, 2026
• - Contact Information: For more details or to register, shareholders should visit the Gross Law Firm's website or contact them directly at the firm’s New York office, located at 15 West 38th Street, 12th Floor, New York, NY 10018. The firm can be reached via email at [email protected] or by phone at (646) 453-8903.

This case represents a crucial opportunity for Ultragenyx investors to hold the company accountable and recover potential losses incurred due to alleged deceptive practices in reporting their drug's clinical efficacy. It’s essential for shareholders to take swift action to ensure their rights are protected.

For those affected, joining this lawsuit may be a crucial step toward recovery and accountability in corporate governance practices. Don't miss the opportunity to make your voice heard in this important legal battle.